2016-002509-21
A randomized, open-label, multicenter, phase III, 2-arm study comparing efficacy and tolerability of the intensified variant ‘dose-dense/dose-intense ABVD’ (ABVD DD-DI) with an interim PET response-adapted ABVD program as upfront therapy in advanced-stage
Pdf
Stampa
W06 Ricerca farmaco
Titolo/oggetto del contratto di sperimentazione
A randomized, open-label, multicenter, phase III, 2-arm study comparing efficacy and tolerability of the intensified variant ‘dose-dense/dose-intense ABVD’ (ABVD DD-DI) with an interim PET response-adapted ABVD program as upfront therapy in advanced-stage
Codice EUDRACT
2016-002509-21
Promotore
Fondazione Italiana Linfomi ONLUS (FIL)
Codice del protocollo del promotore
FIL- Rouge
Data di nullaosta
04-07-2017
Data sottoscrizione del contratto
14-07-2017
Data di chiusura
Budget
0,00
Rimborsi
0,00
Totale
0,00
note
Data ultima modifica
19-02-2020 14:47:35
Pincipal investigators
Nome Unità Operativa
Ematologia Rimini
Nome principal investigator
Anna Lia Molinari
Principal investigator
Anna Lia Molinari Ematologia di Rimini
CV Principal investigator